A novel dressing seeded with embryonic artery CD133+ cells and loaded with the Sirt1 agonist SRT1720 accelerates the healing of diabetic ischemic ulcers

Cheng,Pan‑Ke; Chen,Xiao‑Long; Su,Xing‑Xing; Su,Xue‑Jiao; Hou,Chun‑Li

doi:10.3892/etm.2018.6099

A novel dressing seeded with embryonic artery CD133+ cells and loaded with the Sirt1 agonist SRT1720 accelerates the healing of diabetic ischemic ulcers

Authors:
- Pan‑Ke Cheng
- Xiao‑Long Chen
- Xing‑Xing Su
- Xue‑Jiao Su
- Chun‑Li Hou
View Affiliations

Affiliations: Department of Anatomy, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: April 25, 2018 https://doi.org/10.3892/etm.2018.6099
Pages: 5243-5250
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Refractory ischemic ulcers that occur in patients with diabetes present a major clinical challenge. Embryonic artery cluster of differentiation 133+ cells (EACCs) may promote the healing of diabetic ulcers; however, the high glucose environment in the diabetic ulcers decreases the survival rate of transplanted EACCs and inhibit their biological function. Furthermore, microcirculation in diabetic ischemic ulcers is impaired, which inhibits the beneficial effect of EACCs. In the current study, the Sirt1 agonist SRT1720 was selected as a therapeutic drug and loaded into a dressing composed of PLGA, collagen and silk (PCSS) formed using electrospinning technology. EACCs were seeded onto the PCSS dressing and this was used to treat diabetic ulcers. The results indicated that SRT1720 promotes the proliferation of EACCs, enhances the secretion of vascular endothelial growth factor A, interluekin 8 and basic fibroblast growth factor, and inhibits the secretion of tumor necrosis factor α. Furthermore, SRT1720 promoted the paracrine function of EACCs and promoted the proliferation and migration of human umbilical vein endothelial cells. PCSS induced the steady release of SRT1720 over a 15‑day period and PCSS seeded with EACCs (PCSS‑EACCs) were transplanted into the diabetic ischemic ulcers of mice with diabetes. The results of these experiments indicated that angiogenesis and the healing of diabetic ischemic ulcers was significantly improved following the transplantation of PCSS‑EACCs. Therefore, PCSS‑EACCs may be a novel and effective treatment for diabetic ischemic ulcers.

View Figures

View References

1	Murad MH, Haydour Q and Benkhadra K: ACP journal club. Review: In patients with chronic diabetic foot ulcers, hyperbaric oxygen reduces major amputations. Ann Intern Med. 159:JC92013. View Article : Google Scholar : PubMed/NCBI
2	Kolossváry E, Bánsághi Z, Szabó GV, Járai Z and Farkas K: Ischemic origin of diabetic foot disease. Epidemiology, difficulties of diagnosis, options for prevention and revascularization. Orv Hetil. 158:203–211. 2017.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
3	Yang S, Geng Z, Ma K, Sun X and Fu X: Efficacy of topical recombinant human epidermal growth factor for treatment of diabetic foot ulcer: A systematic review and meta-analysis. Int J Low Extrem Wounds. 15:120–125. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhao WN, Xu SQ, Liang JF, Peng L, Liu HL, Wang Z, Fang Q, Wang M, Yin WQ, Zhang WJ and Lou JN: Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model. Metabolism. 65:1755–1767. 2016. View Article : Google Scholar : PubMed/NCBI
5	Barcelos LS, Duplaa C, Kränkel N, Graiani G, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M, et al: Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res. 104:1095–1102. 2009. View Article : Google Scholar : PubMed/NCBI
6	Lawall H and Diehm C: Diabetic foot syndrome from the perspective of angiology and diabetology. Orthopade. 38:1149–1159. 2009.(In German). View Article : Google Scholar : PubMed/NCBI
7	Ascione R and Madeddu P: Risk and benefit of CD133+ progenitors. Circ Res. 105:e22009. View Article : Google Scholar : PubMed/NCBI
8	Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A and Koya D: Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets. 14:622–636. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kume S, Kitada M, Kanasaki K, Maegawa H and Koya D: Anti-aging molecule, Sirt1: A novel therapeutic target for diabetic nephropathy. Arch Pharm Res. 36:230–236. 2013. View Article : Google Scholar : PubMed/NCBI
10	Nimmagadda VK, Makar TK, Chandrasekaran K, Sagi AR, Ray J, Russell JW and Bever CT Jr: SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review. J Neuroimmunol. 304:29–34. 2017. View Article : Google Scholar : PubMed/NCBI
11	Kumar A and Chauhan S: How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem. 119:45–69. 2016. View Article : Google Scholar : PubMed/NCBI
12	Milner J: Cellular regulation of SIRT1. Curr Pharm Des. 15:39–44. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chang HC and Guarente L: SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 25:138–145. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cao Y, Jiang X, Ma H, Wang Y, Xue P and Liu Y: SIRT1 and insulin resistance. J Diabetes Complications. 30:178–183. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P and Lee SO: IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat Oncol. 10:2272015. View Article : Google Scholar : PubMed/NCBI
16	Abitan H, Bohr H and Buchhave P: Correction to the beer-lambert-bouguer law for optical absorption. Appl Opt. 47:5354–5357. 2008. View Article : Google Scholar : PubMed/NCBI
17	Seliktar D: Designing cell-compatible hydrogels for biomedical applications. Science. 336:1124–1128. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wallach D: The TNF cytokine family: One track in a road paved by many. Cytokine. 63:225–229. 2013. View Article : Google Scholar : PubMed/NCBI
19	McFee RM and Cupp AS: Vascular contributions to early ovarian development: Potential roles of VEGFA isoforms. Reprod Fertil Dev. 25:333–342. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lan CC, Wu CS, Huang SM, Wu IH and Chen GS: High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: New insights into impaired diabetic wound healing. Diabetes. 62:2530–2538. 2013. View Article : Google Scholar : PubMed/NCBI
21	Nakamizo S, Egawa G, Doi H, Natsuaki Y, Miyachi Y and Kabashima K: Topical treatment with basic fibroblast growth factor promotes wound healing and barrier recovery induced by skin abrasion. Skin Pharmacol Physiol. 26:22–29. 2013. View Article : Google Scholar : PubMed/NCBI
22	Bus SA: The role of pressure offloading on diabetic foot ulcer healing and prevention of recurrence. Plast Reconstr Surg. 138 Suppl 3:179S–187S. 2016. View Article : Google Scholar : PubMed/NCBI
23	Boulton AJ, Vileikyte L, Ragnarson-Tennvall G and Apelqvist J: The global burden of diabetic foot disease. Lancet. 366:1719–1724. 2005. View Article : Google Scholar : PubMed/NCBI
24	Futrega K, King M, Lott WB and Doran MR: Treating the whole not the hole: Necessary coupling of technologies for diabetic foot ulcer treatment. Trends Mol Med. 20:137–142. 2014. View Article : Google Scholar : PubMed/NCBI
25	Fiordaliso F, Clerici G, Maggioni S, Caminiti M, Bisighini C, Novelli D, Minnella D, Corbelli A, Morisi R, De Iaco A and Faglia E: Prospective study on microangiopathy in type 2 diabetic foot ulcer. Diabetologia. 59:1542–1548. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ndip A, Ebah L and Mbako A: Neuropathic diabetic foot ulcers-evidence-to-practice. Int J Gen Med. 5:129–134. 2012.PubMed/NCBI
27	Şener LT and Albeniz I: Challenge of mesenchymal stem cells against diabetic foot ulcer. Curr Stem Cell Res Ther. 10:530–534. 2015. View Article : Google Scholar : PubMed/NCBI
28	Bheda P, Jing H, Wolberger C and Lin H: The substrate specificity of sirtuins. Annu Rev Biochem. 85:405–429. 2016. View Article : Google Scholar : PubMed/NCBI
29	Kwon HS and Ott M: The ups and downs of SIRT1. Trends Biochem Sci. 33:517–525. 2008. View Article : Google Scholar : PubMed/NCBI
30	Imai S and Guarente L: NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24:464–471. 2014. View Article : Google Scholar : PubMed/NCBI
31	Huber JL, McBurney MW, Distefano PS and McDonagh T: SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem. 2:1751–1759. 2010. View Article : Google Scholar : PubMed/NCBI
32	Villalba JM, de Cabo R and Alcain FJ: A patent review of sirtuin activators: An update. Expert Opin Ther Pat. 22:355–367. 2012. View Article : Google Scholar : PubMed/NCBI